| Detailed information |
|---|
| CancerLivER ID | 2116 |
| Biomarker | miR-128-2 |
| Biomarker Name/Symbol (given in Publication) | miR-128-2 |
| Biomolecule | miRNA |
| Subject | Human |
| Degree of Validity | Biomarker for the overall survival prediction of patients with hepatocellular carcinoma and validated on independent dataset |
| Experimental Condition | HCC v/s Normal, predict survival of patients |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC tissues |
| Level of significance | p < 0.01 |
| Source | Serum |
| PMID | 25642945 |
| Type of Biomarker | Prognostic |
| Pathway | NA |
| Cohort | Training dataset :20 patients with portal vein tumor thrombosis (PVTT) and 20 patients without PVTT; validation dataset: 182 patients |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2015 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |